Research Achievements

Presentations and Postersby Voluntary Organization JBCRG

2008


Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: Results of a multicenter phase II trial: JBCRG03 trial


Sato N, Iwata H, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Toi M; Japan Breast Cancer Research Group (JBCRG)


6th European Breast Cancer Conference, Poster, Berlin (Germany), Apr. 2008

Back to Association JBCRG page